2033eP Exploring diversity in patient and caregiver treatment preferences for tyrosine kinase inhibitors (TKIs) in stage 4 ALK+ non-small cell lung cancer (NSCLC).

Saved in:
Bibliographic Details
Title: 2033eP Exploring diversity in patient and caregiver treatment preferences for tyrosine kinase inhibitors (TKIs) in stage 4 ALK+ non-small cell lung cancer (NSCLC).
Authors: Culver, K.W.1 (AUTHOR), Seo, J.2 (AUTHOR), Trapali, M.3 (AUTHOR), Clarke, H.2 (AUTHOR), Whitty, J.3 (AUTHOR), Sethi, A.4 (AUTHOR), Cherepanov, D.5 (AUTHOR), Farmen, S.6 (AUTHOR), Danes, C.G.7 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1155-S1155. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.2655